
Commercialization of rare & orphan products in Switzerland and smaller EU Markets
Unlocking economic opportunities: commercializing rare & orphan products in Switzerland and beyond the EU’s big five
Rare and orphan diseases present significant challenges and opportunities for healthcare systems worldwide, but recent developments in Switzerland and the smaller EU markets have led to new opportunities.
In this paper we cover:
- How recent policy changes are making market access more difficult for orphan drugs.
- How Switzerland’s position as the third-fastest country for reimbursing new medicines post-approval, coupled with its simplified authorization procedure, make it an attractive market for biotech companies.
- The diverse types of access programs available in Switzerland and the EU.
- The unique opportunities for orphan drug commercialization in Switzerland and other smaller EU markets.
Download this paper for actionable insights to help navigate the complex commercialization landscape for orphan drugs in Switzerland and the smaller EU markets.

About Sciensus
Sciensus is a leading European life sciences organisation with over 30 years of experience connecting patients with life-changing medications. We’re redefining patient-centric care, connecting patients with life-changing medicines while empowering pharmaceutical companies and healthcare professionals with the insights needed to improve people’s lives.
Read more on…

Events
World Orphan Drug Congress USA 2025
Sciensus is proud to sponsor the upcoming World Orphan Drug Congress USA 2025. The World Orphan Drug Congress is a…

Thought Leadership
Expand into Europe: unlocking the orphan drug market

Blogs
Rare disease day 2025
What is rare disease day? Rare disease day was founded in 2008 by EURORDIS – Rare diseases Europe and the…